Clinical trials: Endocrine Disorder
Type 1 Diabetes
DIabetic Retinopathy Candesartan Trials.
The primary objective is to determine whether candesartan, compared to placebo reduces the progression of diabetic retinopathy in normotensive, normoalbuminuric type 1 diabetic patients with retinopathy.
- Trial name
- DIRECT (NCT00252720)
- Testing
- candesartan
- Volunteers
- 1,850 people
- Sponsor
- AstraZeneca
Diabetes, Diabetes Mellitus, Type 2
To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1c
This trial is conducted in North America (the United States of America (USA) and Mexico). The trial is designed to evaluate the effects of treatment with liraglutide versus glimepiride in subjects with type 2 diabetes.
- Trial name
- LEAD-3 (NCT00294723)
- Testing
- liraglutide, glimepiride
- Where
- 117 sites in United States, Mexico and 1 more
- Volunteers
- 746 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Insulin Glulisine Administered Pre-meal Versus Post-meal in Adult Subjects With Type 2 Diabetes Mellitus Receiving Insulin Glargine as Basal Insulin
The purpose of this study is to compare the change in weight from baseline to study week 52 in the per-protocol population of pre-meal insulin glulisine (Apidra) versus post-meal Apidra, in patients receiving insulin glargine…
- Trial name
- NCT00135096
- Testing
- insulin glulisine, insulin glargine
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Sanofi
Thyroid Eye Disease
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
A multicenter clinical study to evaluate the efficacy and safety of IBI311 in subjects with inactive thyroid eye disease. The study consists of two parts, with a maximum duration of approximately 64 weeks.
- Trial name
- NCT07113262
- Testing
- IBI311
- Where
- China
- Volunteers
- 111 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Type 2 Diabetes Mellitus
A Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia
The purpose of this study is to measure the effect of retatrutide versus placebo, administered every week, on time to recovery from hypoglycemia during hypoglycemic clamp in participants with Type 2 Diabetes Mellitus (T2DM)…
- Trial name
- NCT06982846
- Testing
- Retatrutide
- Where
- Austria
- Volunteers
- 80 people
- Sponsor
- Eli Lilly and Company
Metastatic Pancreatic Cancer
YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer
In Phase 1b study, six subjects will be enrolled in Arm A (YL-13027 + AG regimen) and Arm B (HY-0102 + AG regimen). The first 12 subjects will be evaluated for safety after one cycle.
- Trial name
- NCT06662669
- Testing
- YL-13027, HY-0102, Gemcitabine
- Volunteers
- 120 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Type 2 Diabetes Mellitus, Hypertension
HYZAAR vs. Ramipril for Diabetes (0954A-245)(COMPLETED)
A study to test the safety and efficacy of HYZAAR as compared to Ramipril in patients with type 2 diabetes mellitus (high blood sugar) and hypertension (high blood pressure).
- Trial name
- NCT00480805
- Testing
- MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks, Comparator : ramipril /Duration of Treatment : 8 Weeks
- Volunteers
- 312 people
- Sponsor
- Organon and Co
Acromegaly
Study Comparing SOM230 Subcutaneously and Sandostatin Subcutaneously in Acromegalic Patients
5 month study comparing SOM230 s.c. and Sandostatin s.c. in acromegalic patients.
- Trial name
- NCT00088582
- Testing
- Pasireotide (SOM230), Octreotide (Sandostatin)
- Where
- 5 sites in United States
- Volunteers
- 62 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 1
The Efficacy and Safety of Liraglutide as Adjunct Therapy to Insulin in the Treatment of Type 1 Diabetes
This trial is conducted globally. The aim of the trial is to confirm the efficacy and safety of liraglutide as adjunct therapy to insulin in the treatment of type 1 diabetes.
- Trial name
- ADJUNCT ONE™ (NCT01836523)
- Testing
- liraglutide
- Where
- 182 sites in United States, Argentina and 15 more
- Volunteers
- 1,398 people
- Sponsor
- Novo Nordisk A/S
Metastatic Pancreatic Cancer
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
To evaluate the efficacy of surufatinib combined with camrelizumab, nab-paclitaxel, and gemcitabine versus nab-paclitaxel plus gemcitabine as the first-line treatment in metastatic pancreatic cancer
- Trial name
- NCT06361888
- Testing
- Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine, Nab-paclitaxel Plus Gemcitabine, Surufatinib with Nab-paclitaxel, and Gemcitabine
- Where
- 52 sites in China
- Volunteers
- 502 people
- Sponsor
- Hutchmed
Growth Hormone Disorder, Adult Growth Hormone Deficiency
French National Registry of Adults With Growth Hormone Deficiency Treated With Somatropin
This study is conducted in Europe. The aim of this study is to extract data from the French National Registry holding information about patients having initiated growth hormone therapy with the objective to describe patients…
- Trial name
- NCT01580605
- Testing
- somatropin
- Where
- France
- Volunteers
- 331 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study to Examine Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients With Type 2 Diabetes
Exenatide twice daily has been studied in Japanese type 2 diabetes patients. A once-weekly version of exenatide is currently being evaluated. Study GWBW is the first study of exenatide once weekly in Japanese patients.
- Trial name
- NCT00612794
- Testing
- exenatide once weekly
- Where
- 4 sites in Japan
- Volunteers
- 30 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A 30 Day Acute Efficacy and Safety Study of Chromium Picolinate + Biotin on Glycemic Control in Overweight or Obese Subjects With T2DM
The purpose of the proposed work is to assess the effects of a dietary supplement, containing chromium (600 mcg per day) provided by chromium picolinate and biotin (2 mg per day) on glycemic control in type 2 diabetes.
- Trial name
- NCT00308451
- Testing
- Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Nutrition 21, Inc.
Type 2 Diabetes Mellitus
A Study to Assess Insulin Delivery With PaQ® in Patients With Type 2 Diabetes Mellitus
The purpose of the study is to obtain an assessment (efficacy, safety, and patient reported outcomes) of basal bolus insulin delivery with PaQ in insulin-using patients with type 2 diabetes mellitus (T2DM).
- Trial name
- NCT02419859
- Testing
- PaQ® Insulin Delivery Device, Insulin, Asp(B28)-
- Where
- Austria
- Volunteers
- 20 people
- Sponsor
- CeQur Corporation
Type 2 Diabetes
Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study, which aims to provide data on the efficacy and safety of HDM1002 tablets in adults with type 2 diabetes mellitus (T2DM) inadequately…
- Trial name
- NCT07193459
- Testing
- HDM1002 200 mg, HDM1002 400 mg
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Diabetes, Diabetes Mellitus, Type 1
Investigating the Postprandial Glucose Metabolism After Treatment With Faster-acting Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Europe. The aim of the trial is to investigate the postprandial glucose metabolism after treatment with faster-acting insulin aspart in subjects with type 1 diabetes.
- Trial name
- NCT02568280
- Testing
- Faster-acting insulin aspart, insulin aspart
- Where
- Austria
- Volunteers
- 42 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
A Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes With Inadequately Controlled Hypertension on an ACEI or ARB and an Additional Antihypertensive Medication
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting…
- Trial name
- NCT01195662
- Testing
- Dapagliflozin
- Where
- 298 sites in United States, Australia and 14 more
- Volunteers
- 2,245 people
- Sponsor
- AstraZeneca
Type 2 Diabetes
A Study of Tirzepatide (LY3298176) Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine With or Without Metformin
The purpose of this study is to compare the safety and efficacy of the study drug tirzepatide to placebo in participants with type 2 diabetes that are already on insulin glargine, with or without metformin.
- Trial name
- SURPASS-5 (NCT04039503)
- Testing
- Tirzepatide
- Where
- 48 sites in United States, Czechia and 6 more
- Volunteers
- 475 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Type 2
Dose-Range Finding Study for MK0893 (0893-008)
A study to compare MK0893 to metformin or placebo for patients with Type 2 diabetes (Diabetes Mellitus).
- Trial name
- NCT00479466
- Testing
- MK0893, Metformin
- Volunteers
- 342 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Malignancies, NSCLC
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit…
- Conditions
- Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer
- Trial name
- NCT05059522
- Testing
- Avelumab, Lorlatanib, Talazoparib
- Where
- 71 sites in United States, Australia and 17 more
- Volunteers
- 77 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.